Orchestrating diabetic wound repair via mitochondria-targeted delivery of dihydromyricetin with tailored ADSC-derived biohybrid nanovesicles - PubMed
3 hours ago
- #diabetic wound repair
- #biohybrid nanovesicles
- #mitochondrial targeting
- The study addresses the therapeutic failure in diabetic wounds due to a disconnect between antioxidant signaling and mitochondrial repair.
- A biohybrid nanovesicle (DHM@mtABV) was developed by fusing ADSC-derived nanovesicles with synthetic liposomes, encapsulating dihydromyricetin (DHM) and a mitochondria-targeting ligand (TPP).
- DHM@mtABV demonstrated high biocompatibility and effective mitochondrial accumulation, breaking the cycle of oxidative stress by scavenging ROS and activating the NRF2 pathway.
- Treatment with DHM@mtABV restored mitochondrial membrane potential, calcium homeostasis, and enhanced cellular proliferation and migration under oxidative stress.
- In a diabetic mouse model, DHM@mtABV significantly accelerated wound closure, offering a transformative approach for treating refractory diabetic wounds.